Single-use technology means big cost savings for bioprocessing industry

June 21, 2016 Erin Righetti

 

single-use-biotech

What does adoption of single-use technology mean for the bioprocessing industry?

The R&D and manufacturing of biologics and biosimilars is extremely expensive due to the amount of detail necessary to replicate and ensure validation of biosynthesis of living cells and their components. It can take an average of 10 years and USD 2.7 billion per drug, according to Wolfgang Kuhne, VP, Technical Development Bioprocessing and Clinical Supply at Roche Diagnostics, as quoted in a recent blog post on Knect365 Bioprocessing blog. The post, entitled, “Single-use technology: The future of the bioprocessing industry?”, gives additional perspectives from leading industry figures, or see a featured infographic on the benefits of single-use technologies.

Single-use technologies are disposable and provide significant time and cost savings as they eliminate cleaning validation steps and provide upstream and downstream solutions. A big benefit, in addition to reduced costs, is the increased flexibility that makes single-use technologies an increasingly attractive prospect for many. How? The sale up process. Single use technologies significantly reduce the development timeline from regulatory to market adoption.

 


Want to elevate your brand and connect with potential partners? The Cell & Gene Exchange brings together leaders from patient advocacy groups, industry, academia and government to network, exchange ideas and explore partnership opportunities. Learn more here. 

Previous Video
BIO-Europe Spring® 2016: What alliance opportunities excite Genentech?
BIO-Europe Spring® 2016: What alliance opportunities excite Genentech?

Dr. Thomas Zioncheck, senior director of Genentech Partnering (a unit of Roche subsidiary Genentech Inc.), ...

Next Video
BIO-Europe Spring® 2016: AZ BioVenture Hub CEO says aim is an innovative ecosystem
BIO-Europe Spring® 2016: AZ BioVenture Hub CEO says aim is an innovative ecosystem

AstraZeneca’s BioVentureHub CEO Magnus Björsne tells Mike Ward, global director of content for Informa Phar...